AgomAb Therapeutics NV (AGMB) stock
AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.82−0.10 (-1.69%)
Close on Nov 18, 2026Market cap $145.50KP/E –Yield –
AgomAb Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -€59.28M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€59.28M | – |
| FY2024 | Dec 31, 2024 | -€48.02M | – |
| FY2023 | Dec 31, 2023 | -€31.19M | – |
See a number that looks wrong?